Selected article for: "human papilloma virus and papilloma virus"
Author: Devi Dayal; Saniya Gupta
Title: Connecting BCG Vaccination and COVID-19: Additional Data
  • Document date: 2020_4_8
    • ID: by4aefjc_12
    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20053272 doi: medRxiv preprint simplex virus and human papilloma virus, a favourable in vitro or in vivo effect has indeed been observed in various studies (11). Based on the hypothesis that BCG vaccination may induce (partial) protection against susceptibility to and/or severity of SARS-CoV-2 infection even during the epidemic, some c.....
    Document: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20053272 doi: medRxiv preprint simplex virus and human papilloma virus, a favourable in vitro or in vivo effect has indeed been observed in various studies (11). Based on the hypothesis that BCG vaccination may induce (partial) protection against susceptibility to and/or severity of SARS-CoV-2 infection even during the epidemic, some countries like Australia and the Netherlands which do not practice routine BCG vaccination have been really quick to launch phase 3 clinical trials (12, 13).

    Search related documents:
    Co phrase search for related documents
    • BCG vaccination and routine BCG vaccination: 1, 2, 3, 4, 5
    • BCG vaccination and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
    • BCG vaccination and SARS infection severity: 1, 2
    • BCG vaccination and susceptibility protection: 1
    • BCG vaccination and vivo effect: 1
    • clinical trial and human papilloma: 1
    • clinical trial and human papilloma virus: 1
    • clinical trial and phase launch: 1, 2
    • clinical trial and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • clinical trial and SARS infection severity: 1, 2, 3, 4, 5, 6, 7
    • clinical trial and vivo effect: 1
    • epidemic SARS infection severity and SARS infection: 1
    • epidemic SARS infection severity and SARS infection severity: 1
    • partial susceptibility protection and susceptibility protection: 1
    • routine BCG vaccination and SARS infection: 1
    • SARS infection and susceptibility protection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • SARS infection and vivo effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • SARS infection severity and susceptibility protection: 1
    • SARS infection severity and vivo effect: 1